Start here if you're new
what it is
Pfizer sells prescription drugs and vaccines, then uses that cash to fund the next wave of treatments.
how it gets paid
Last year Pfizer made $62.6B in revenue.
why growth slowed
Revenue fell 1.6% last year. $3.15 matters most because that is the 2025 adjusted EPS model.
what just happened
Pfizer posted $45.0B in latest-quarter revenue and $1.65 EPS, while the most recent consensus beat was $0.66 versus $0.58 expected.
At a glance
A balance sheet — strong enough to weather a downturn
20/100 earnings predictability — expect surprises
8.4x trailing p/e — the market's not buying it — or you found a deal
6.7% dividend yield — cash in your pocket every quarter
13.5% return on capital — nothing to write home about
xvary composite: 68/100 — average
What they do
Pfizer sells prescription drugs and vaccines, then uses that cash to fund the next wave of treatments.
Pfizer wins on scale. It has 81,000 employees and sells across Primary Care, Specialty Care, and Oncology, so one weak product does not wreck your whole thesis. Operating margin → profit after running the business → so what: Pfizer keeps 36 cents of every sales dollar before interest and taxes.
How they make money
$62.6B
annual revenue · revenue declined -1.6% last year
total revenue
$62.6B
1.6%
The products that matter
commercial medicines portfolio
core portfolio
$62.6B company revenue base
Eliquis and Vyndaqel helped offset part of the COVID decline, but the total business still slipped 1.6% on $62.6B of revenue. That tells you the commercial base is holding up, not yet reaccelerating.
cash engine
cost structure reset
cost program
$4.5B savings target
Management says the cost program is on track to deliver $4.5B by the end of 2025. That's what is keeping adjusted earnings near the current $3.00–$3.15 outlook while revenue rebuilds.
earnings support
future revenue replacement
pipeline
~$30B to replace
The pipeline matters because roughly $30B of revenue faces patent expirations over the next five years. You do not need a miracle here. You need enough launches to stop the top line from shrinking.
the real bet
Key numbers
6.7%
dividend yield
You are being paid far more than the S&P 500 yield while you wait for the earnings reset to play out.
8.4x
trailing p/e
P/E → price relative to profit → so what: the market is pricing Pfizer like a low-growth utility, not a drug giant.
$57.4B
long-term debt
That debt load is the bill for buying growth. If the pipeline works, it looks smart. If not, it hangs over the stock.
36.0%
operating margin
That is still a fat margin after the COVID unwind. Pfizer is not broken. It is in a messy reset.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 85 / 100
- long-term debt $57.4B (28% of capital)
- net profit margin 30.2% — keeps 30 cents of every dollar in revenue
- return on equity 20% — $0.20 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in PFE 3 years ago → it's now worth $5,870.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Pfizer posted $45.0B in latest-quarter revenue and $1.65 EPS, while the most recent consensus beat was $0.66 versus $0.58 expected.
The rebound looks huge because the comparison year was ugly. Revenue rose 170% vs. prior year and EPS rose 166%, while management's cost cuts helped push full-year 2025 adjusted EPS toward $3.15.
$17.1B
revenue
$1.65
eps
170%
revenue growth
the number that mattered
$3.15 matters most because that is the 2025 adjusted EPS model, up from $1.41 in 2024. That is the whole recovery story in one number.
-
pfizer was carrying some momentum heading into the final stanza of 2025.the new york city-based drugmaker surpassed earnings expectations in the second and third quarters, with leadership raising its forecast on each occasion.
-
much of the recent upside to wall street’s estimates has been fueled by benefits from an aggressive cost-cutting strategy, which the company highlighted remains on track to deliver $4.5 billion in anticipated savings by the end of 2025.strength across core franchises eliquis and vyndaqel were also catalysts, helping to mitigate significant erosion in covid-19 product demand.
-
our model calls for full-year adjusted earnings to reach $3.15 a share.this is at the high-end of pfizer’s current $3.00-$3.15 outlook, and represents a modest uptick from $3.11 reported in 2024. as mentioned in the footnotes, we have shifted our presentation to reflect non-gaap earnings beginning in 2025. this metric aims to provide a clearer view of a company’s financial performance by excluding restructuring expenses, intangible asset charges, and various other items that can distort results from core operations.
-
the company closed a major deal to bolster its obesity drug pipeline.pfizer finalized its $10 billion acquisition of metsera last month after a contentious bidding war with novo nordisk.
-
the transaction provides several promising late-stage weight-loss therapies.metsera could help pfizer better compete in what has been a highly lucrative market in recent years.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk for Pfizer right now is failing to replace revenue lost to expiring drug patents. A low multiple and a high yield only help if the $62.6B revenue base stops sliding.
med
patent cliff math
Roughly $30B of revenue faces patent expirations over the next five years. That is nearly half of today's $62.6B revenue base.
If replacement products arrive too slowly, revenue can fall even if the current portfolio executes well.
med
cost cuts masking weak growth
The company says $4.5B of savings are on track by the end of 2025. Savings help EPS. They do not create new demand.
If the top line keeps falling after the cost program is finished, the earnings bridge turns into a dead end.
med
dividend pressure
A 6.7% yield and a $1.77 annual dividend make the stock look patient-friendly. That only works if earnings stay resilient.
The dividend is an asset while adjusted EPS sits around $3.00–$3.15. It becomes a debate if revenue erosion accelerates.
med
pipeline timing
The moat is the pipeline, but the snapshot data here is thin on individual late-stage assets. That uncertainty is real, not a formatting problem.
When investors cannot clearly map the next revenue wave, the stock keeps trading like a value trap until management proves otherwise.
These risks sit on top of $57.4B of long-term debt and a business that just posted a 1.6% revenue decline. Pfizer has room to absorb a stumble. It does not have room for five years of shrugging.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue needs to flatten
The last annual print was $62.6B, down 1.6%. If the next few reports still show contraction, the cheap multiple is sending the right message.
calendar
end-2025 cost program delivery
Management says $4.5B of savings are on track by the end of 2025. You want that target hit without the business looking hollow underneath it.
risk
the $30B replacement problem
Patent expirations over the next five years are the real scoreboard. Watch for evidence that new launches can offset that revenue hole.
trend
institutional selling trend
Institutions were net sellers for two straight quarters, including 1,290 buyers versus 1,312 sellers in 3Q2025. Not a mass exit. Still not a vote of confidence.
Analyst rankings
earnings predictability
20 / 100
Low predictability. In human-speak: you should expect earnings to be lumpy while Pfizer works through the post-COVID reset.
price stability
85 / 100
The stock has been more stable than the story. That is useful if you care about income, less useful if you are waiting for a rerating.
risk rank
2
A low risk rank means the balance sheet and business durability still screen better than most stocks, even if the growth outlook does not.
source: institutional data
Institutional activity
institutions have been net selling for 2 consecutive quarters — 1,290 buyers vs. 1,312 sellers in 3q2025. total institutional holdings: 3.6B shares. net selling for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$23
$46
$26
current price
$35
target midpoint · +32% from current · 3-5yr high: $45 (+70% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive
PFE
xvary deep dive
long
composite 68/100
$35
+32% upside from current price
8.4x
trailing p/e
$64B
2028 revenue est
6.7%
dividend yield
what the street is missing
Wall Street sees a cheap stock. It may be missing that Pfizer only needs to look less bad for this to work. A move from $1.41 in 2024 EPS to $3.15 in 2025 already changes the story.
intrinsic value
At 8.4x trailing earnings, you are not paying for heroics. You are paying for a business with a 36.0% operating margin, a 6.7% yield, and an 18-month target of $35.
This thesis breaks if earnings fail to hold near the $3.15 to $3.20 range or if debt stays heavy without revenue growth. No growth plus $57.4B of debt is how cheap gets cheaper.
what's in the full report
Why 8.4x earnings is the setup
The debt math after Seagen
COVID fade versus core drug demand
Why cost cuts matter more now
Oncology is the real swing factor
What a 6.7% yield is saying
The numbers behind the $35 target
What kills the long case
read the full report
from $5/mo · cancel anytime